Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 747-752

  Liu, Caigang ^a   Zhang, Hao ^a   Shuang, Chen ^b   Lu, Yang ^a   Jin, Feng ^a   Xu, Huimian ^a   Lu, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Maternal and Child Health Hospital of Jinzhou   (China)

Author keywords

Breast cancer; Immunohistochemistry; Markers; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; PROTEIN P53; ESTROGEN; ESTROGEN RECEPTOR; HER2 PROTEIN, HUMAN; PROGESTERONE; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST DUCT; BREAST DUCTAL CARCINOMA IN SITU; BREAST INVASIVE DUCTAL CARCINOMA; CANCER GROWTH; CLINICAL FEATURE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; AGED; BIOSYNTHESIS; BREAST TUMOR; CELL TRANSFORMATION; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INTRADUCTAL CARCINOMA; METABOLISM; MIDDLE AGED; NEOPLASM; PAGET NIPPLE DISEASE; PATHOLOGY; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENES, P53; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956925140     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9279-8     Document Type: Article

References (30)

1. JT Anim B John SS Abdulsathar A Prasad T Saji N Akhtar, et al. 2005 Relationship between the expression of various markers and prognostic factors in breast cancer Acta Histochem 107 2 87 93 10.1016/j.acthis.2005.01.002 15950051 1:CAS:528:DC%2BD2MXmvVaks7Y%3D (Pubitemid 40799007)
2. M Kasami T Uematsu M Honda T Yabuzaki J Sanuki Y Uchida, et al. 2008 Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy Breast 17 523 527 10.1016/j.breast.2008.04.002 18534850
3. J Kurebayashi T Otsuki H Kunisue K Tanaka S Yamamoto H Sonoo 2000 Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer Clin Cancer Res 6 512e8
4. A Rody R Diallo C Poremba C Speich P Wuelfing S Kissler, et al. 2004 Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast Oncol Rep 12 695 699 15375487 1:CAS:528:DC%2BD2cXovFaisr4%3D
5. MR Hussein SR Abd-Elwahed AR Abdulwahed 2008 Alterations of estrogen receptors progesterone receptors, and c-erbB2 oncogene protein expression in ductal carcinomas of the breast Cell Biol Int 32 698 707 10.1016/j.cellbi.2008. 01.007 18296077 1:CAS:528:DC%2BD1cXmtVSnurw%3D
6. Q Su S Hu H Gao R Ma Q Yang Z Pan, et al. 2008 Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells Oncology 75 159 168 10.1159/000159267 18827493 1:CAS:528:DC%2BD1cXhsVKju7zO
7. CA Lange 2008 Challenges to defining a role for progesterone in breast cancer Steroids 73 914 921 10.1016/j.steroids.2007.12.023 18243264 1:CAS:528:DC%2BD1cXmvFensb0%3D
8. I Vanden Bempt P Van Loo M Drijkoningen P Neven A Smeets MR Christiaens, et al. 2008 Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing J Clin Oncol 26 4869 4874 10.1200/JCO.2007.13.4296
9. FS Al-Joudi ZA Iskandar J Rusli 2008 The expression of p53 in invasive ductal carcinoma of the breast: a study in the North-East States of Malaysia Med J Malaysia 63 96 99 18942291 1:STN:280:DC%2BD1cnotFSnsA%3D%3D
10. P Meijnen JL Peterse N Antonini EJ Rutgers MJ van de Vijver 2008 Immunohistochemical categorisation of ductal carcinoma in situ of the breast Br J Cancer 98 137 142 10.1038/sj.bjc.6604112 18043578 1:CAS:528: DC%2BD1cXisF2qsw%3D%3D
11. SS Ko YS Na CS Yoon JY Park HS Kim MH Hur, et al. 2007 The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node-negative breast cancer: a tissue microarray study Int J Surg Pathol 15 98 109 10.1177/1066896906299124 17478762 1:CAS:528:DC%2BD2sXksVOmurk%3D (Pubitemid 46548106)
12. L Ayadi A Khabir H Amouri S Karray A Dammak M Guermazi, et al. 2008 Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma World J Surg Oncol 6 112 10.1186/1477-7819-6-112 18945339
13. CK Anders DS Hsu G Broadwater CR Acharya JA Foekens Y Zhang, et al. 2008 Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression J Clin Oncol 26 3324 3330 10.1200/JCO.2007.14.2471 18612148
14. D Lafkas G Trimis AG Papavassiliou H Kiaris 2008 P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy Int J Cancer 123 967 971 10.1002/ijc.23546 18512237 1:CAS:528:DC%2BD1cXovFWmu7Y%3D (Pubitemid 352032428)
15. MS Al-Ahwal 2006 HER-2 positivity and correlations with other histopathologic features in breast cancer patients-hospital based study J Pak Med Assoc 56 65 68 16555637
16. J Horiguchi Y Koibuchi K Iijima T Yoshida M Yoshida D Takata, et al. 2003 Immunohistochemical double staining with estrogen receptor and HER-2 on primary breast cancer Int J Mol Med 12 855 859 14612957 1:CAS:528:DC%2BD3sXpvFansb8%3D
17. MR Hussein 2005 Transforming growth factor-beta and malignant melanoma: molecular mechanisms J Cutan Pathol 32 389 395 10.1111/j.0303-6987.2005.00356.x 15953371 (Pubitemid 40853000)
18. N Todorovic-Rakovic 2005 TGF-beta 1 could be a missing link in the interplay between ER and HER-2 in breast cancer Med Hypotheses 65 546 551 10.1016/j.mehy.2005.03.019 15913903 1:CAS:528:DC%2BD2MXlvFynt7s%3D (Pubitemid 40956954)
19. KB Ewan HA Oketch-Rabah SA Ravani G Shyamala HL Moses MH Barcellos-Hoff 2005 Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice Am J Pathol 167 409 417 16049327 1:CAS:528:DC%2BD2MXpsVeqtr8%3D
20. E Papadopoulou K Anagnostopoulos G Tripsianis I Tentes S Kakolyris G Galazios, et al. 2008 Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism Neoplasma 55 229 238 18348656 1:CAS:528:DC%2BD1MXhtFyitLo%3D
21. KJ Lauritsen HJ List R Reiter A Wellstein AT Riegel 2002 A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells Oncogene 21 47 7147 7155 10.1038/sj.onc.1205943 12370804 1:CAS:528:DC%2BD38XnsFyksro%3D (Pubitemid 35305601)
22. W Jin Y Chen GH Di P Miron YF Hou H Gao ZM Shao 2008 Estrogen receptor (ER) beta or p53 attenuates ER{alpha}-mediated transcriptional activation on the BRCA2 promoter J Biol Chem 283 29671 29680 10.1074/jbc.M802785200 18765668 1:CAS:528:DC%2BD1cXht1ynt7vM
23. J Rhee SW Han DY Oh JH Kim SA Im W Han, et al. 2008 The clinicopathologic characteristics, prognostic significance of triple-negativity in node-negative breast cancer BMC Cancer 8 307 10.1186/1471-2407-8-307 18947390 1:CAS:528:DC%2BD1cXhtl2jtb%2FK
24. D Maru LP Middleton S Wang V Valero A Sahin 2005 HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger Cancer 103 900 905 10.1002/cncr.20850 15643600 1:CAS:528: DC%2BD2MXisVensro%3D (Pubitemid 40270066)
25. M Coccaro G Gallucci 2008 Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer J Clin Oncol 26 3288 10.1200/JCO.2008.17.3203 18591567
26. Y Belkacémi J Gligorov M Ozsahin H Marsiglia B De Lafontan H Laharie-Mineur, et al. 2008 Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study Ann Oncol 19 1110 1116 10.1093/annonc/mdn029 18344537 (Pubitemid 351796336)
27. KC Lear-Kaul HR Yoon BK Kleinschmidt-DeMasters L McGavran M Singh 2003 Her-2/neu status in breast cancer metastases to the central nervous system Arch Pathol Lab Med 127 1451 1457 14567724 1:CAS:528:DC%2BD3sXpsVCru70%3D
28. SM Pupa E Tagliabue S Menard A Anichini 2005 HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine J Cell Physiol 205 10 18 10.1002/jcp.20387 15887236 1:CAS:528:DC%2BD2MXhtVSktbvE (Pubitemid 41262846)
29. E Rahko G Blanco Y Soini, et al. 2003 A mutant Tp53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients Eur J Cancer 39 447 453 10.1016/S0959-8049(02)00499-9 12751374 1:CAS:528:DC%2BD3sXhtVemurg%3D (Pubitemid 36173688)
30. L Chesler DD Goldenberg R Collins M Grimmer GE Kim T Tihan, et al. 2008 Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction Neoplasia 10 1268 1274 18953436 1:CAS:528: DC%2BD1cXhtlagtrzL